Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices

Trial Profile

An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Richter's syndrome
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 15 Jun 2023 Results of five year interim analysis assessing effectiveness and safety data of blinatumomab in these pts presented at the 28th Congress of the European Haematology Association
    • 23 Mar 2022 Status changed from recruiting to active, no longer recruiting.
    • 30 Nov 2021 Planned End Date changed from 22 Mar 2024 to 21 Mar 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top